Posted on: 27 September 2022
CNWL's Dima Abdulrahim, Addctions Quality Lead, and Owen Bowden-Jones, Consultant Psychiatrist, CNWL and Honorary Professor, UCL, have released a new book on addictions called Textbook of Clinical Management of Club Drugs and Novel Psychoactive Substances.
There are global concerns about the proliferation and misuse of club drugs and novel psychoactive substances, yet we know little about their harms and research on clinical management and treatment remains limited.
The book fills the knowledge gap by providing a detailed overview of the research evidence available to date. It provides a framework that allows readers to understand this large number of new drugs, using classifications based on primary psychoactive effect.
Within this framework, the book provides detailed reviews of the more commonly used drugs. Each chapter explores pharmacology, patterns and mode of use, acute and chronic harms, and clinical interventions supported by research evidence.
An invaluable resource for clinical staff, this book will support clinicians working in the emergency department, substance misuse and addiction services, mental health services, primary care, sexual health services and more.
It will also be of interest to academics and those developing drug policy.
Below is a review of the book
This book is a welcome addition to the previous 2015 NEPTUNE guidance. It provides a unique learning experience on what all clinicians should know about the misuse of club drugs and novel psychoactive substances.
Capturing the latest trends of a dynamic drug market, the authors pulled together the best available evidence on a variety of substances to support the improvement of clinical practice.
Whether you consult chapters of special interest or read the entire book, you can be assured that you will have been exposed to the most comprehensive work available on the clinical management of the harms of novel psychoactive substances. Highly recommended.' Ornella Corazza, Ph.D., Professor of Addiction Science, University of Hertfordshire, UK, and President of the International Society for the Study of Emerging Drug